Sun, May 22, 2011
Fri, May 20, 2011
Thu, May 19, 2011
Wed, May 18, 2011
Tue, May 17, 2011
Mon, May 16, 2011
Sun, May 15, 2011
[ Sun, May 15th 2011 ] - Market Wire
Teva to Acquire Taiyo
Fri, May 13, 2011
Thu, May 12, 2011
Wed, May 11, 2011
Tue, May 10, 2011
Mon, May 9, 2011
Sun, May 8, 2011
Sat, May 7, 2011
Fri, May 6, 2011
Thu, May 5, 2011
Wed, May 4, 2011
Tue, May 3, 2011
Mon, May 2, 2011
Fri, April 29, 2011
Thu, April 28, 2011
Wed, April 27, 2011
Tue, April 26, 2011
Mon, April 25, 2011
Fri, April 22, 2011

SuperGen to Present at Noble Financial Capital Markets Equity Conference on May 17th


//health-fitness.news-articles.net/content/2011/ .. pital-markets-equity-conference-on-may-17th.html
Published in Health and Fitness on Tuesday, May 10th 2011 at 3:21 GMT by Market Wire   Print publication without navigation


DUBLIN, Calif.--([ BUSINESS WIRE ])--SuperGen, Inc. (NASDAQ:SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that Michael V. McCullar, Ph.D., senior vice president, strategy and discovery operations, will present at Noble Financial Capital Marketsa™ Seventh Annual Equity Conference on Tuesday, May 17th in Florida.

SuperGen's presentation will begin at 10:30 a.m. ET. A live audio and high-definition video webcast of the presentation will be available in the Investor Events section of the Company's website at [ www.supergen.com ]. SuperGen recommends registering at least ten minutes before the presentation to download the free presentation viewer program. The webcast will be archived for 90 days.

About SuperGen

SuperGen is a pharmaceutical company dedicated to discovery and development of novel cancer therapeutics in epigenetic and cell signaling modulation. The Company develops products through biochemical and clinical proof of concept to partner for further development and commercialization. On April 6, 2011, SuperGen entered into a definitive merger agreement to acquire Astex Therapeutics Limited, a UK based biotechnology company. The transaction is subject to customary regulatory, legal and shareholder approvals. For more information about SuperGen, please visit [ http://www.supergen.com ].


Publication Contributing Sources